The HIV-1 transgenic rat model of neuroHIV

Brain, Behavior, and Immunity

Volumn 48, Issue , 2015, Pages 336-349

  Vigorito, Michael ^a   Connaghan, Kaitlyn P ^a   Chang, Sulie L ^a  

^a SETON HALL UNIVERSITY   (United States)

Author keywords

HIV 1 transgenic rat; NeuroHIV; Substance abuse

Indexed keywords

ACETYLCHOLINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METHAMPHETAMINE; MORPHINE; NICOTINE; PATTERN RECOGNITION RECEPTOR; PSYCHOTROPIC AGENT; RANTES; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VPR PROTEIN; VPU PROTEIN;

ADAPTIVE IMMUNITY; ALCOHOL ABUSE; ANIMAL BEHAVIOR; ANTIVIRAL THERAPY; BEHAVIOR CHANGE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; CITRIC ACID CYCLE; COGNITION; COMORBIDITY; CORPUS STRIATUM; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; EFFECTOR CELL; EXECUTIVE FUNCTION; EXPLORATORY BEHAVIOR; GENE EXPRESSION; HABITUATION; HELPER CELL; HIPPOCAMPUS; HIV 1TG RAT; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPHENOTYPING; INNATE IMMUNITY; LENTIVIRINAE; LIFE EXPECTANCY; LOCOMOTION; LONG TERM EXPOSURE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MENTAL HEALTH; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PLACE PREFERENCE; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT MODEL; REVIEW; SCID MOUSE; SENSORY GATING; SPLEEN FUNCTION; SUBSTANCE ABUSE; TRANSGENE; TRANSGENIC RAT; VIRUS ENTRY; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSMISSION; WEIGHT GAIN; WORKING MEMORY; ANIMAL; DISEASE MODEL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; PSYCHOLOGY;

AIDS DEMENTIA COMPLEX; ANIMALS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; MICE; RATS; RATS, TRANSGENIC;

EID: 84941770474     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.02.020     Document Type: Review

References (204)

1. Abbondanzo, S.J., Chang, S.L., 2014. HIV-1 transgenic rats display alterations in immunophenotype and cellular responses associated with aging. PLoS ONE 9(8), e105256.
2. Acharjee, S.N., Noorbakhsh, F., Stemkowski, P.L., Olechowski, C., Cohen, E.A., Ballanyi, K., Kerr, B., Pardo, C., Smith, P.A., Power, C., 2010. HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB J. 24 (11), 4343-4353.
3. Akdag, S.J., Nestor, P.G., et al., 2003. The startle reflex in schizophrenia: habituation and personality correlates. Schizophr. Res. 64 (2-3), 165-173.
4. Akkina, R., 2013. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435 (1), 14-28.
5. Aller, M.A., Arias, J.L., et al., 2001. Neuro-immune-endocrine functional system and vascular pathology. Med. Hypotheses 57 (5), 561-569.
6. Ances, B.M., Ortega, M., Vaida, F., Heaps, J., Paul, R., 2012. Independent effects of HIV, aging, and HAART on brain volumetric measures. J. Acquir. Immune Defic. Syndr. 59 (5), 469-477.
7. Antinori, A., Arendt, G., Becker, J.T., Brew, B.J., Byrd, D.A., Cherner, M., Clifford, D.B., Cinque, P., Epstein, L.G., Goodkin, K., Gisslen, M., Grant, I., Heaton, R.K., Joseph, J., Marder, K., Marra, C.M., McArthur, J.C., Nunn, M., Price, R.W., Pulliam, L., Robertson, K.R., Sacktor, N., Valcour, V., Wojna, V.E., 2007. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69 (18), 1789-1799.
8. Aoyama, K., McSweeney, F.K., 2001. Habituation contributes to within-session changes in free wheel running. J. Exp. Anal. Behav. 76 (3), 289-302.
9. Ateh, E.N., Goicochea, M., Davis, H., Davenport, J., DeTolla, L.J., Yutaka, T., Bryant, J.L., 2014. The HIV-1 transgenic nude rat: a model of pneumocystis pneumonia. Int. Res. J. Biol. Sci. 3 (5), 10-18.
10. Avraham, H.K., Jiang, S., Lee, T.H., Prakash, O., Avraham, S., 2004. HIV-1 Tatm-ediated effects on focal adhesion assembly and permeability in brain microvascular endothelial cells. J. Immunol. 173 (10), 6228-6233.
11. Baddeley, A., 1996. The fractionation of working memory. Proc. Natl. Acad. Sci. 93 (24), 13468-13472.
12. Balleine, B.W., O'Doherty, J.P., 2010. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 35 (1), 48-69.
13. Banks, W.A., 2015. The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav. Immun. 44, 1-8.
14. Banks, W.A., Ercal, N., Price, T.O., 2006. The blood-brain barrier in neuroAIDS. Curr. HIV Res. 4 (3), 259-266.
15. Bardi, G., Sengupta, R., Khan, M.Z., Patel, J.P., Meucci, O., 2006. Human immunodeficiency virus gp120-induced apoptosis of human neuroblastoma cells in the absence of CXCR4 internalization. J. Neurovirol. 12 (3), 211-218.
16. Becker, J.T., Sanders, J., et al., 2011. Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav. 5 (2), 77-85.
17. Bettcher, B.M., Kramer, J.H., 2014. Longitudinal inflammation, cognitive decline, and Alzheimer's disease: a mini-review. Clin. Pharmacol. Ther. 96 (4), 464-469.
18. Bilbo, S.D., Schwarz, J.M., 2009. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front. Behav. Neurosci. 3, 14.
19. Bland, S.T., Beckley, J.T., et al., 2010. Neonatal Escherichia coli infection alters glial, cytokine, and neuronal gene expression in response to acute amphetamine in adolescent rats. Neurosci. Lett. 474 (1), 52-57.
20. Borner, C., Kraus, J., et al., 2004. Transcriptional regulation of the human mu-opioid receptor gene by interleukin-6. Mol. Pharmacol. 66 (6), 1719-1726.
21. Braff, D.L., Geyer, M.A., et al., 2001. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156 (2-3), 234-258.
22. Brew, B.J., Crowe, S.M., et al., 2009. Neurodegeneration and ageing in the HAART era. J. Neuroimmune Pharmacol. 4 (2), 163-174.
23. Byrd, D., Murray, J., et al., 2012. Impact of opiate addiction on neuroinflammation in HIV. J. Neurovirol. 18 (5), 364-373.
24. Cao, J., Wang, S., et al., 2013. RNA deep sequencing analysis reveals that nicotine restores impaired gene expression by viral proteins in the brains of HIV-1 transgenic rats. PLoS One 8 (7), e68517.
25. Carey, A.N., Sypek, E.I., Singh, H.D., Kaufman, M.J., McLaughlin, J.P., 2012. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav. Brain Res. 229 (1), 48-56.
26. Catani, M.V., Corasaniti, M.T., Navarra, M., Nistico, G., Finazzi-Agro, A., Melino, G., 2000. Gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors. J. Neurochem. 74 (6), 2373-2379.
27. Cavaillon, J.M., Adib-Conquy, M., 2006. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 10 (5), 233.
28. Cavrois, M., Neidleman, J., et al., 2008. The achilles heel of the trojan horse model of HIV-1 trans-bInfection. PLoS Pathog. 4 (6), e1000051.
29. Cedeno-Laurent, F., Gómez-Flores, M., Mendez, N., Ancer-Rodriguez, J., Bryant, J.L., Gaspari, A.A., Trujillo, J.R., 2011. New insights into HIV-1-primary skin disorders. J. Int. AIDS Soc. 14, 5, 2652-2614-2655.
30. Chander, G., Himelhoch, Seth, Moore, Richard D., 2006. Substance abuse and psychiatric disorders in HIV-positive patients. Drugs 66 (6), 769-789.
31. Chang, S.L., Connaghan, K.P., 2012. Behavioral and molecular evidence for a feedback interaction between morphine and HIV-1 viral proteins. J. Neuroimmune Pharmacol. 7 (2), 332-340.
32. Chang, S.L., Connaghan, K.P., et al., 2014. NeuroHIV and use of addictive substances. Int. Rev. Neurobiol. 118, 403-440.
33. Chang, S.L., Vigorito, M., 2006. Role of HIV-1 infection in addictive behavior: a study of a HIV-1 transgenic rat model. Am. J. Infect. Dis. 2 (2), 98-106.
34. Chang, S.L., Moldow, R.L., et al., 1996a. Morphine affects the brain-immune axis by modulating an interleukin-1 beta dependent pathway. Adv. Exp. Med. Biol. 402, 35-42.
35. Chang, S.L., Patel, N.A., et al., 1996b. FOS expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine. Brain Res. 736 (1-2), 227-236.
36. Chang, S.L., Wu, G.D., et al., 1998. The effects of interaction between morphine and interleukin-1 on the immune response. Adv. Exp. Med. Biol. 437, 67-72.
37. Chang, L., Ernst, T., et al., 2002. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naïve HIV patients. NeuroImage 17(3), 1638-1648.
38. Chang, S.L., Beltran, J.A., et al., 2007a. Expression of the mu opioid receptor in the human immunodeficiency virus type 1 transgenic rat model. J. Virol. 81 (16), 8406-8411.
39. Chang, S.L., Ocasio, F., et al., 2007b. Immunodeficient parameters in the HIV-1 transgenic rat model. Am. J. Infect. Dis. 3 (4), 202-207.
40. Chen, R., Zhou, H., et al., 2005. Differential expression of cytokines in the brain and serum during endotoxin tolerance. J. Neuroimmunol. 163 (1-2), 53-72.
41. Choi, D.Y., Lee, M.K., et al., 2012. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol. Dis. 49C, 159-168.
42. Chompre, G., Cruz, E., Maldonado, L., Rivera-Amill, V., Porter, J.T., Noel Jr., R.J., 2012. Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory. Neurobiol. Disease 49C, 128-136.
43. Chudasama, Y., 2011. Animal models of prefrontal-executive function. Behav. Neurosci. 125 (3), 327-343.
44. Clary, C.R., Guidot, D.M., et al., 2011. Chronic alcohol ingestion exacerbates skeletal muscle myopathy in HIV-1 transgenic rats. AIDS Res. Ther. 8, 30.
45. Crespo, J.A., Sturm, K., et al., 2006. Activation of muscarinic and nicotinic acetylcholine receptors in the nucleus accumbens core is necessary for the acquisition of drug reinforcement. J. Neurosci. 26 (22), 6004-6010.
46. Cui, W.Y., Wang, J., et al., 2012. Modulation of innate immune-related pathways in nicotine-treated SH-SY5Y cells. Amino Acids 43 (3), 1157-1169.
47. Cui, W.Y., Zhao, S., et al., 2013. Identification and characterization of poly(I:C)-induced molecular responses attenuated by nicotine in mouse macrophages. Mol. Pharmacol. 83 (1), 61-72.
48. Cysique, L.A., Maruff, P., Brew, B.J., 2004. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol. 10 (6), 350-357.
49. D'Aversa, T.G., Eugenin, E.A., Berman, J.W., 2005. NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J. Neurosci. Res. 81 (3), 436-446.
50. Denton, P.W., Garcia, J.V., 2011. Humanized mouse models of HIV infection. AIDS Rev. 13 (3), 135-148.
51. D'Hooge, R.F., Franck, F., Mucke, L., De Deyn, P.P., 1999. Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur. J. Neurosci. 11 (12), 4398-4402.
52. Diaz-Gerevini, G.T., Repossi, G., et al., 2014. Cognitive and motor perturbations in elderly with longstanding diabetes mellitus. Nutrition 30 (6), 628-635.
53. Dickie, P., Felser, J., et al., 1991. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185 (1), 109-119.
54. Doyle, K.L., Morgan, E.E., Morris, S., Smith, D.M., Little, S., Iudicello, J.E., Blackstone, K., Moore, D.J., Grant, I., Letendre, S.L., Woods, S.P., Translational Methamphetamine, Aids Research Center Group, 2013. Real-world impact of neurocognitive deficits in acute and early HIV infection. J. Neurovirol. 19 (6), 565-573.
55. Elenkov, I.J., 2007. Effects of catecholamines on the immune response. NeuroImmune Biol. 7, 189-206.
56. El-Hage, N., Podhaizer, E.M., et al., 2011. Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine. Immunol. Invest. 40 (5), 498-522.
57. Fan, X.J., Joshi, P.C., Koval, M., Guidot, D.M., 2011. Chronic alcohol ingestion exacerbates lung epithelial barrier dysfunction in HIV-1 transgenic rats. Alcohol. Clin. Exp. Res. 35 (10), 1866-1875.
58. Fan, X., Staitieh, B.S., Jensen, J.S., Mould, K.J., Greenberg, J.A., Joshi, P.C., Koval, M., Guidot, D.M., 2013. Activating the Nrf2-mediated antioxidant response element restores barrier function in the alveolar epithelium of HIV-1 transgenic rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 305 (3), L267-277.
59. Fattore, L., Cossu, G., et al., 2004. Cannabinoids and reward: interactions with the opioid system. Crit. Rev. Neurobiol. 16 (1-2), 147-158.
60. Fauci, A.S., Folkers, G.K., 2012. Toward an AIDS-free generation. J. Am. Med. Assoc. 308 (4), 343-344.
61. Fitting, S., Booze, R.M., et al., 2006a. Neonatal hippocampal Tat injections: developmental effects on prepulse inhibition (PPI) of the auditory startle response. Int. J. Dev. Neurosci. 24 (4), 275-283.
62. Fitting, S., Booze, R.M., et al., 2006b. Neonatal intrahippocampal glycoprotein 120 injection: the role of dopaminergic alterations in prepulse inhibition in adult rats. J. Pharmacol. Exp. Ther. 318 (3), 1352-1358.
63. Fitting, S., Ignatowska-Jankowska, B.M., Bull, C., Skoff, R.P., Lichtman, A.H., Wise, L.E., Fox, M.A., Su, J., Medina, A.E., Krahe, T.E., Knapp, P.E., Guido, W., Hauser, K.F., 2013. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol. Psychiatry 73 (5), 443-453.
64. Fuchs, F., Damm, J., et al., 2013. Activation of the inflammatory transcription factor nuclear factor interleukin-6 during inflammatory and psychological stress in the brain. J. Neuroinflammation 10, 140.
65. Gala, R.R., 1991. Prolactin and growth hormone in the regulation of the immune system. Proc. Soc. Exp. Biol. Med. 198 (1), 513-527.
66. Galea, I., Bechmann, Ingo, Perry, V. Hugh, 2007. What is immune privilege (not)? Trends Immunol. 28 (1), 12-18.
67. Gao, F., Bailes, E., Robertson, D.L., Chen, Y., Rodenburg, C.M., Michael, S.F., Cummins, L.B., Arthur, L.O., Peeters, M., Shaw, G.M., Sharp, P.M., Hahn, B.H., 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397 (6718), 436-441.
68. Giovannetti, A., Ensoli, F., et al., 1999. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin. Exp. Immunol. 118 (1), 87-94.
69. Glowa, J.R., Panlilio, L.V., Brenneman, D.E., Gozes, I., Fridkin, M., Hill, J.M., 1992. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570 (1-2), 49-53.
70. Gonzalez-Lira, B., Rueda-Orozco, P.E., et al., 2006. Nicotine prevents HIVgp120-caused electrophysiological and motor disturbances in rats. Neurosci. Lett. 394(2), 136-139.
71. Grimm, M.C., Ben-Baruch, A., et al., 1998. Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J. Exp. Med. 188 (2), 317-325.
72. Hadas, E., Borjabad, A., Chao, W., Saini, M., Ichiyama, K., Potash, M.J., Volsky, D.J., 2007. Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1. AIDS 21 (8), 905-909.
73. Hag, A.M., Kristoffersen, U.S., Pedersen, S.F., Gutte, H., Lebech, A.M., Kjaer, A., 2009. Regional gene expression of LOX-1, VCAM-1, and ICAM-1 in aorta of HIV-1 transgenic rats. PLoS One 4 (12), e8170.
74. Hahn, K., Husstedt, I.W., et al., 2010. HIV-associated neuropathies. Nervenarzt 81(4), 409-417.
75. Hargus, N.J., Thayer, S.A., 2013. Human immunodeficiency virus-1 Tat protein increases the number of inhibitory synapses between hippocampal neurons in culture. J. Neurosci. 33 (45), 17908-17920.
76. Henry, B.L., Geyer, M.A., Buell, M., Perry, W., Young, J.W., Minassian, A., Translational Methamphetamine, Aids Research Center Group, 2013. Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav. Brain Res. 236 (1), 210-220.
77. Henry, B.L., Geyer, M.A., Buell, M.R., Perry, W., Young, J.W., Minassian, A., Translational Methamphetamine, Aids Research Center Group, 2014. Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav. Pharmacol. 25 (1), 12-22.
78. Herz, A., 1998. Opioid reward mechanisms: a key role in drug abuse? Can. J. Physiol. Pharmacol. 76 (3), 252-258.
79. Hodges, H., 1996. Maze procedures: the radial-arm and water maze compared. Brain Res. Cogn. Brain Res. 3 (3-4), 167-181.
80. Homji, N.F., Mao, X., Langsdorf, E.F., Chang, S.L., 2012a. Endotoxin-induced cytokine and chemokine expression in the HIV-1 transgenic rat. J. Neuroinflammation 9, 3, 2094-2099-2093.
81. Homji, N.F., Vigorito, M., et al., 2012b. Morphine-induced conditioned place preference and associated behavioural plasticity in HIV-1 transgenic rats. Int. J. Clin. Exp. Med. 5 (2), 105-123.
82. Horuk, R., Martin, A.W., et al., 1997. Expression of chemokine receptors by subsets of neurons in the central nervous system. J. Immunol. 158 (6), 2882-2890.
83. Hosoi, T., Nomura, Y., 2004. Functional role of acetylcholine in the immune system. Front. Biosci. 9, 2414-2419.
84. House, S.D., Mao, X., et al., 2001. Chronic morphine potentiates the inflammatory response by disrupting interleukin-1beta modulation of the hypothalamic-pituitary-adrenal axis. J. Neuroimmunol. 118 (2), 277-285.
85. Jankovic, B.D., Radulovic, J., 1992. Enkephalins, brain and immunity: modulation of immune responses by methionine-enkephalin injected into the cerebral cavity. Int. J. Neurosci. 67 (1-4), 241-270.
86. Joshi, P.C., Guidot, D.M., 2011. HIV-1 transgene expression in rats induces differential expression of tumor necrosis factor alpha and zinc transporters in the liver and the lung. AIDS Res. Ther. 8, 36 (6405-6408-6436).
87. Joshi, P.C., Raynor, R., et al., 2008. HIV-1-transgene expression in rats decreases alveolar macrophage zinc levels and phagocytosis. Am. J. Respir. Cell Mol. Biol. 39 (2), 218-226.
88. June, H.L., Tzeng Yang, A.R., Bryant, J.L., Jones, O., Royal 3rd, W., 2009. Vitamin A deficiency and behavioral and motor deficits in the human immunodeficiency virus type 1 transgenic rat. J. Neurovirol. 15 (5-6), 380-389.
89. Kalivas, P.W., O'Brien, C., 2008. "Drug addiction as a pathology of staged neuroplasticity". Neuropsychopharmacology 33 (1), 166-180.
90. Kass, M., Chang, S.L., 2010. Transgenic rodent models. In: Gendelman, H.E., Grant, I., Everall, I.P., Lipton, S.A., Swindells, S. (Eds.), The Neurology of AIDS. Oxford University Press Inc., New York.
91. Kaul, M., Lipton, S.A., 1999. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl. Acad. Sci. USA 96 (14), 8212-8216.
92. Kesby, J.P., Hubbard, D.T., Markou, A., Semenova, S., 2012. Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict. Biol. 19, 593-605.
93. Kline, E.R., Kleinhen, D.J., Liang, B., Dikalov, S., Guidot, D.M., Hart, C.M., Jones, D.P., Sutliff, R.L., 2008. Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration. Am. J. Physiol. Heart Circ. Physiol. 294 (6), H2792-H2804.
94. Koob, G.F., 2006. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 101 (s1), 23-30.
95. Kopp, J.B., Rooney, J.F., Wohlenberg, C., Dorfman, N., Marinos, N.J., Bryant, J.L., Katz, S.I., Notkins, A.L., Klotman, P.E., 1993. Cutaneous disorders and viral gene expression in HIV-1 transgenic mice. AIDS Res. Hum. Retroviruses 9 (3), 267-275.
96. Kozak, W., Conn, C.A., et al., 1994. Lipopolysaccharide induces fever and depresses locomotor activity in unrestrained mice. Am. J. Physiol. 266 (1 Pt 2), R125-135.
97. Kraus, J., 2009. Regulation of mu-opioid receptors by cytokines. Front. Biosci. 1, 164-170.
98. Krucker, T.T., Toggas, S.M., Mucke, L., Siggins, G.R., 1998. Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience 83 (3), 691-700.
99. Lannuzel, A., Lledo, P.M., Lamghitnia, H.O., Vincent, J.D., Tardieu, M., 1995. HIV-1 envelope proteins gp120 and gp160 potentiate NMDA-induced [Ca2+]i increase, alter [Ca2+]i homeostasis and induce neurotoxicity in human embryonic neurons. Eur. J. Neurosci. 7 (11), 2285-2293.
100. Lashomb, A.L., Vigorito, M., Chang, S.L., 2009. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J. Neurovirol. 15 (1), 14-24.
101. Letendre, S., 2011. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir. Med. 19 (4), 137-142.
102. Lewis, M.D., 2011. Dopamine and the neural "now": essay and review of addiction: a disorder of choice. Perspect. Psychol. Sci. 6 (2), 150-155.
103. Li, S.T., Matsushita, M., Moriwaki, A., Saheki, Y., Lu, Y.F., Tomizawa, K., Wu, H.Y., Terada, H., Matsui, H., 2004. HIV-1 Tat inhibits long-term potentiation and attenuates spatial learning [corrected. Ann. Neurol. 55 (3), 362-371.
104. Li, M.D., Cao, J., et al., 2013. Transcriptome sequencing of gene expression in the brain of the HIV-1 transgenic rat. PLoS One 8 (3), e59582.
105. Lindl, K.A., Marks, D.R., et al., 2010. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J. Neuroimmune Pharmacol. 5(3), 294-309.
106. Liu, Y., Jones, M., Hingtgen, C.M., Bu, G., Laribee, N., Tanzi, R.E., Moir, R.D., Nath, A., He, J.J., 2000. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 6 (12), 1380-1387.
107. Liu, X., Chang, L., et al., 2009. Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. J. Neuroimmune Pharmacol. 4 (3), 309-316.
108. Mahajan, S.D., Schwartz, S.A., et al., 2002. Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J. Immunol. 169 (7), 3589-3599.
109. Marcotte, T.D.G.I., 2009. Neuropsychology of Everyday Functioning. Guilford Press, New York.
110. Gonda, Matthew A., Luther, D. Gene, et al., 1994. Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res. 32 (2), 155-181.
111. Maung, R., Medders, K.E., Sejbuk, N.E., Desai, M.K., Russo, R., Kaul, M., 2012. Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury. J. Neuroimmune Pharmacol. 7 (2), 306-318.
112. McSweeney, F.K., Murphy, E.S., 2009. Sensitization and habituation regulate reinforcer effectiveness. Neurobiol. Learn. Mem. 92 (2), 189-198.
113. Meazza, C., Pagani, S., et al., 2004. Effect of growth hormone (GH) on the immune system. Pediatr. Endocrinol. Rev. 1 (Suppl. 3), 490-495.
114. Midde, N.M., Gomez, A.M., Harrod, S.B., Zhu, J., 2011. Genetically expressed HIV-1 viral proteins attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB signaling in rats. Pharmacol. Biochem. Behav. 98 (4), 587-597.
115. Minassian, A., Henry, B.L., Woods, S.P., Vaida, F., Grant, I., Geyer, M.A., Perry, W., 2013. Prepulse inhibition in HIV-associated neurocognitive disorders. J. Int. Neuropsychol. Soc. 19 (6), 709-717.
116. Mind Exchange Working G, 2013. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin. Infect. Dis. 56 (7), 1004-1017.
117. Mocroft, A., Katlama, C., Johnson, A.M., Pradier, C., Antunes, F., Mulcahy, F., Chiesi, A., Phillips, A.N., Kirk, O., Lundgren, J.D., 2000. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 356 (9226), 291-296.
118. Moran, L.M., Aksenov, M.Y., et al., 2012. Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr. HIV Res. 10 (5), 415-424.
119. Moran, L.M., Booze, R.M., et al., 2013. Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp. Neurol. 239, 139-147.
120. Moran, L.M.B., Rosemarie, M., Mactutus, Charles F., 2014. Animal Models: Behavior and Pathology: Preclinical Assessment of the Putative Cognitive Deficits in HAND. Current Laboratory Methods in Neuroscience Research. Springer, pp. 541-565.
121. Morch, H., Pedersen, B.K., 1995. Beta-endorphin and the immune system - possible role in autoimmune diseases. Autoimmunity 21 (3), 161-171.
122. Nath, A., Hauser, K.F., Wojna, V., Booze, R.M., Maragos, W., Prendergast, M., Cass, W., Turchan, J.T., 2002. Molecular basis for interactions of HIV and drugs of abuse. J. Acquir. Immune Defic. Syndr. 31 (Suppl. 2), S62-S69.
123. National Institute of Health (2014, November 1, 2014). Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.
124. Nazari, R., Joshi, S., 2008. CCR5 as target for HIV-1 gene therapy. Curr. Gene Ther. 8(4), 264-272.
125. Nazari, R., Ma, X.Z., et al., 2008. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA. J. Gen. Virol. 89 (Pt 9), 2252-2261.
126. Nemeth, C.L., Glasper, E.R., et al., 2014. Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats. PLoS One 9 (10), e108399.
127. Nischang, M., Gers-Huber, G., et al., 2012. Modeling HIV infection and therapies in humanized mice. Swiss Med. Wkly 142 (1).
128. Ocasio, F.M., Jiang, Y., et al., 2004. Chronic morphine accelerates the progression of lipopolysaccharide-induced sepsis to septic shock. J. Neuroimmunol. 149 (1-2), 90-100.
129. Olmsted, R.A., Hirsch, V.M., et al., 1989. Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc. Natl. Acad. Sci. USA 86 (20), 8088-8092.
130. Otis, J.S., Ashikhmin, Y.I., Brown, L.A., Guidot, D.M., 2008. Effect of HIV-1-related protein expression on cardiac and skeletal muscles from transgenic rats. AIDS Res. Ther. 5, 8, 6405-6405-6408.
131. Ottaviani, E., Franchini, A., et al., 1999. ACTH and its role in immuneneuroendocrine functions. A comparative study. Curr. Pharm. Des. 5 (9), 673-681.
132. Pacheco, R., Riquelme, E., et al., 2010. Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. Cent. Nerv. Syst. Agents Med. Chem. 10 (1), 65-83.
133. Patel, C.A., Mukhtar, M., Pomerantz, R.J., 2000. Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J. Virol. 74 (20), 9717-9726.
134. Peng, J., Vigorito, M., et al., 2010. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J. Neuroimmunol. 218 (1), 94-101.
135. Picciotto, M.R., Zoli, M., 2002. Nicotinic receptors in aging and dementia. J. Neurobiol. 53 (4), 641-655.
136. Picciotto, M.R., Brunzell, D.H., et al., 2002. Effect of nicotine and nicotinic receptors on anxiety and depression. NeuroReport 13 (9), 1097-1106.
137. Poluektova, L., Makarov, E., 2014. Humanized mice. In: Xiong, H., Gendelman, H.E. (Eds.), Current Laboratory Methods in Neuroscience Research. Springer, New York, pp. 483-495.
138. Potash, M.J., Chao, W., et al., 2005. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc. Natl. Acad. Sci. USA 102 (10), 3760-3765.
139. Pruznak, A.M., Hong-Brown, L., Lantry, R., She, P., Frost, R.A., Vary, T.C., Lang, C.H., 2008. Skeletal and cardiac myopathy in HIV-1 transgenic rats. Am. J. Physiol. Endocrinol. Metabol. 295 (4), 964-973.
140. Qiu, Y., Peng, Y., et al., 1996. Immunoregulatory role of neurotransmitters. Adv. Neuroimmunol. 6 (3), 223-231.
141. Rankin, C.H., Abrams, T., et al., 2009. Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol. Learn. Mem. 92 (2), 135-138.
142. Rao, J.S., Kim, H.W., et al., 2011. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J. Neuroinflammation 8, 101.
143. Rao, V.R., Ruiz, A.P., Prasad, V.R., 2014. Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res. Ther. 11, 13, 6405-6411-6413. eCollection 2014.
144. Ray, P.E., Liu, X.H., et al., 2003. A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy. Kidney Int. 63 (6), 2242-2253.
145. Reddy, P.V., Gandhi, N., Samikkannu, T., Saiyed, Z., Agudelo, M., Yndart, A., Khatavkar, P., Nair, M.P., 2012. HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder. Neurochem. Int. 61 (5), 807-814.
146. Reid, W., Sadowska, M., Denaro, F., Rao, S., Foulke Jr., J., Hayes, N., Jones, O., Doodnauth, D., Davis, H., Sill, A., O'Driscoll, P., Huso, D., Fouts, T., Lewis, G., Hill, M., Kamin-Lewis, R., Wei, C., Ray, P., Gallo, R.C., Reitz, M., Bryant, J., 2001. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl. Acad. Sci. USA 98 (16), 9271-9276.
147. Reid, W., Abdelwahab, S., Sadowska, M., Huso, D., Neal, A., Ahearn, A., Bryant, J., Gallo, R.C., Lewis, G.K., Reitz, M., 2004. HIV-1 transgenic rats develop T cell abnormalities. Virology 321 (1), 111-119.
148. Repunte-Canonigo, V., Lefebvre, Celine, George, Olivier, Kawamura, Tomoya, Morales, Marisela, Koob, George, Califano, Andrea, Masliah, Eliezer, Sanna, Pietro, 2014. Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol. Neurodegener. 9 (1), 26.
149. Resnick, L., Berger, J.R., Shapshak, P., Tourtellotte, W.W., 1988. Early penetration of the blood-brain-barrier by HIV. Neurology 38 (1), 9-14.
150. Roberts, A.J.M., Maung, R., Sejbuk, N.E., Ake, C., Kaul, M., 2010. Alteration of Methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J. Neurosci. Methods 186 (2), 222-225.
151. Robertson, K.R., Smurzynski, M., Parsons, T.D., Wu, K., Bosch, R.J., Wu, J., McArthur, J.C., Collier, A.C., Evans, S.R., Ellis, R.J., 2007. "The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21 (14), 1915-1921.
152. Robinson, T.E., Berridge, K.C., 2000. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 (S2), 91-117.
153. Robinson, T.E., Berridge, K.C., 2008. Review. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363(1507), 3137-3146.
154. Rogers, T.J., Peterson, P.K., 2003. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol. 24 (3), 116-121.
155. Ronaldson, P.T., Bendayan, R., 2006. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol. Pharmacol. 70 (3), 1087-1098.
156. Rossier, J., Grobéty, M.-C., et al., 2000. Spacial learning by rats across visually disconnected environments. Anim. Learn. Behav. 28 (1), 16-27.
157. Royal 3rd, W., Wang, H., et al., 2007. A vitamin A deficient diet enhances proinflammatory cytokine, Mu opioid receptor, and HIV-1 expression in the HIV-1 transgenic rat. J. Neuroimmunol. 185 (1-2), 29-36.
158. Royal 3rd, W., Zhang, L., Guo, M., Jones, O., Davis, H., Bryant, J.L., 2012. Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. J. Neuroimmunol. 247 (1-2), 16-24.
159. Russo, S.J., Dietz, D.M., et al., 2010. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 33 (6), 267-276.
160. Ruzicka, B.B., Thompson, R.C., et al., 1996. Interleukin-1 beta-mediated regulation of mu-opioid receptor mRNA in primary astrocyte-enriched cultures. J. Neurochem. 66 (1), 425-428.
161. Sarkar, S., Mao, X., et al., 2013. Age- and ethanol concentration-dependent effects of acute binge drinking in the HIV-1 transgenic rat. Alcohol. Clin. Exp. Res. 37(Suppl 1), E70-78.
162. Schmitz, J.E., Kuroda, M.J., et al., 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (5403), 857-860.
163. Schouten, J., Cinque, P., Gisslen, M., Reiss, P., Portegies, P., 2011. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25 (5), 561-575.
164. Shah, A., Kumar, A., 2010. HIV-1 gp120-mediated increases in IL-8 production in astrocytes are mediated through the NF-kappaB pathway and can be silenced by gp120-specific siRNA". J. Neuroinflammation 7, 96, 2094-2097-2096.
165. Shah, A., Singh, D.P., et al., 2011a. HIV-1 envelope protein gp120 up regulates CCL5 production in astrocytes which can be circumvented by inhibitors of NF-kappaB pathway. Biochem. Biophys. Res. Commun. 414 (1), 112-117.
166. Shah, A., Verma, A.S., Patel, K.H., Noel, R., Rivera-Amill, V., Silverstein, P.S., Chaudhary, S., Bhat, H.K., Stamatatos, L., Singh, D.P., Buch, S., Kumar, A., 2011b. HIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. PloS One 6 (6), e21261.
167. Shin, A.H., Thayer, S.A., 2013. Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol. Cell. Neurosci. 54, 22-29.
168. Staikos, L., Malellari, L., et al., 2008. Lipopolysaccharide-induced pro-inflammatory cytokines in the brain of rats in the morphine-tolerant state. J. Neuroimmune Pharmacol. 3 (4), 236-240.
169. Strathdee, S.A., Hallett, T.B., et al., 2010. HIV and risk environment for injecting drug users: the past, present, and future. The Lancet 376 (9737), 268-284.
170. Suvisaari, J., Mautemps, N., et al., 2003. Childhood central nervous system viral infections and adult schizophrenia. Am. J. Psychiatry 160 (6), 1183-1185.
171. Swerdlow, N.R., Geyer, M.A., 1998. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24 (2), 285-301.
172. Theodore, S., Cass, W.A., et al., 2007. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr. HIV Res. 5 (3), 301-313.
173. Toggas, S.M., Masliah, E., Rockenstein, E.M., Rall, G.F., Abraham, C.R., Mucke, L., 1994. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367 (6459), 188-193.
174. Tomaszewska, D., Przekop, F., 1997. The immune-neuro-endocrine interactions. J. Physiol. Pharmacol. 48 (2), 139-158.
175. Toneatto, S., Finco, O., van der Putten, H., Abrignani, S., Annunziata, P., 1999. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 13 (17), 2343-2348.
176. Torregrossa, M.M., Corlett, P.R., et al., 2011. Aberrant learning and memory in addiction. Neurobiol. Learn. Mem. 96 (4), 609-623.
177. Torres, L., Noel, R.J., 2014. Astrocytic expression of HIV-1 viral protein R in the hippocampus causes chromatolysis, synaptic loss and memory impairment. J. neuroinflam. 11, 53 (2094-2011-2053).
178. Tran, P.B., Miller, R.J., 2003. Chemokine receptors: signposts to brain development and disease. Nat. Rev. Neurosci. 4 (6), 444-455.
179. Trigo, J.M., Martin-Garcia, E., et al., 2010. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 108 (3), 183-194.
180. Trillo-Pazos, G., McFarlane-Abdulla, E., Campbell, I.C., Pilkington, G.J., Everall, I.P., 2000. Recombinant nef HIV-IIIB protein is toxic to human neurons in culture. Brain Res. 864 (2), 315-326.
181. Tsakok, M., Stolp, H., et al., 2012. Investigating the impaired sensorimotor gating in adult mice following foetal exposure to inflammatory mediators. BMC Proc. 6(Suppl. 4), 49.
182. Typlt, M., Mirkowski, M., et al., 2013. Habituation of reflexive and motivated behaviour in mice with deficient BK channel function. Front. Integr. Neurosci. 7(79).
183. van Maanen, M., Sutton, R.E., 2003. Rodent models for HIV-1 infection and disease. Curr. HIV Res. 1 (1), 121-130.
184. Vance, D.E., McDougall Jr., G.J., et al., 2014. Cognitive consequences of aging with HIV: implications for neuroplasticity and rehabilitation. Top. Geriatric Rehabil. 30 (1), 35-45.
185. VandeWoude, S., Apetrei, C., 2006. Going wild: lessons from naturally occurring Tlymphotropic lentiviruses. Clin. Microbiol. Rev. 19 (4), 728-762.
186. Vidal, Erich L., Patel, Nilesh A., Wu, Gao-de, Fiala, Milan, Chang, Sulie L., 1998. Interleukin-1 induces the expression of mu opioid receptors in endothelial cells. Immunopharmacol. 38, 261-266.
187. Vigorito, M., Chang, S.L., 2006. Role of HIV-1 infection in addictive behavior: a study of a HIV-1 transgenic rat model. Am. J. Infect. Dis. 2, 98-106.
188. Vigorito, M., LaShomb, A.L., Chang, S.L., 2007. Spatial learning and memory in HIV-1 transgenic rats. J. Neuroimmune Pharmacol. 2 (4), 319-328.
189. Vigorito, M., Cao, J., Li, M.D., Chang, S.L., 2013. Acquisition and long-term retention of spatial learning in the human immunodeficiency virus-1 transgenic rat: effects of repeated nicotine treatment. J. Neurovirol. 19 (2), 157-165.
190. Vila, N., Castillo, J., et al., 2000. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 31 (10), 2325-2329.
191. Viviani, B., Boraso, M., Marchetti, N., Marinovich, M., 2014. Perspectives on neuroinflammation and excitotoxicity: a neurotoxic conspiracy? Neurotoxicology 43, 10-20.
192. Walsh, R.N., Cummins, R.A., 1976. The open-field test: a critical review. Psychol. Bull. 83 (3), 482.
193. Wei, P., Garber, M.E., et al., 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92 (4), 451-462.
194. Wichmann, M.A., Cruickshanks, K.J., et al., 2014. Long-term systemic inflammation and cognitive impairment in a population-based cohort. J. Am. Geriatr. Soc. 62(9), 1683-1691.
195. Wiley, C.A., Achim, C.L., Christopherson, C., Kidane, Y., Kwok, S., Masliah, E., Mellors, J., Radhakrishnan, L., Wang, G., Soontornniyomkij, V., 1999. HIV mediates a productive infection of the brain. AIDS 13 (15), 2055-2059.
196. Woods, S.P., Moore, D.J., Weber, E., Grant, I., 2009. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol. Rev. 19 (2), 152-168.
197. Wybran, J., 1985. Enkephalins and endorphins as modifiers of the immune system: present and future. Fed. Proc. 44 (1 Pt 1), 92-94.
198. Yadav, A., Pati, S., Nyugen, A., Barabitskaja, O., Mondal, P., Anderson, M., Gallo, R.C., Huso, D.L., Reid, W., 2006. HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation. Virology 353 (2), 357-365.
199. Yadav, A., Fitzgerald, P., Sajadi, M.M., Gilliam, B., Lafferty, M.K., Redfield, R., Reid, W., 2009. Increased expression of suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology 385 (1), 126-133.
200. Yirmiya, R., Goshen, I., 2011. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25 (2), 181-213.
201. Yu-Lee, L.Y., 1997. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 215 (1), 35-52.
202. Yu-Lee, L.Y., 2002. Prolactin modulation of immune and inflammatory responses. Recent Prog. Horm. Res. 57, 435-455.
203. Zhang, L., Su, L., 2012. HIV-1 immunopathogenesis in humanized mouse models. Cell. Mol. Immunol. 9 (3), 237-244.
204. Zimmerman, A.W., Jyonouchi, H., et al., 2005. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr. Neurol. 33 (3), 195-201.